Yonhap Infomax News2d ago
Ildong Pharmaceutical appoints Dr. Park Jae-hong, former Dong-A ST CSO with extensive global pharma experience at Janssen, Takeda, and Boehringer Ingelheim, as new R&D president to oversee drug development operations starting next month
#YonhapInfomax #IldongPharmaceutical #ParkJaehong #RDChief #PharmaceuticalIndustry #DrugDevelopment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=113278
Ildong Pharmaceutical Appoints Dr. Park Jae-hong as New R&D Chief

Ildong Pharmaceutical appoints Dr. Park Jae-hong, former Dong-A ST CSO with extensive global pharma experience at Janssen, Takeda, and Boehringer Ingelheim, as new R&D president to oversee drug development operations starting next month

Yonhap Infomax
Yonhap Infomax NewsJan 27
Il-Dong Pharmaceutical Co. reported a 48% jump in 2025 operating profit to KRW 19.4 billion, despite a sales decline, as cost restructuring boosted profitability.
#YonhapInfomax #IlDongPharmaceutical #OperatingProfit #NetProfit #Sales #BusinessRestructuring #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102283
Il-Dong Pharmaceutical Posts 48% Surge in 2025 Operating Profit to KRW 19.4 Billion

Il-Dong Pharmaceutical Co. reported a 48% jump in 2025 operating profit to KRW 19.4 billion, despite a sales decline, as cost restructuring boosted profitability.

Yonhap Infomax